Other Events ·
Radiopharm Theranostics seeks shareholder approval for 10% equity placement capacity under Listing Rule 7.1A
RDPTFRadiopharm Theranostics Ltd
Radiopharm Theranostics Limited is seeking shareholder approval at its Annual General Meeting on November 25, 2026, to renew the Omnibus Incentive Plan and obtain a special resolution granting additional capacity to issue equity securities up to 10% of issued capital over a 12-month period under ASX Listing Rule 7.1A. The company also seeks approval for director Bruce Goodwin's election and advisory adoption of the Remuneration Report. If approved, the company could raise funds for drug manufacturing, clinical trials, and general working capital by issuing shares at no less than 75% of the volume-weighted average price. Radiopharm Theranostics Limited operates in the radiopharmaceutical theranostics sector.